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Background: More than half of patients with melanoma that has spread to regional lymph nodes develop recurrent
disease within the first 3 years after surgery. The aim of the study was to improve disease-free survival (DFS) and
overall survival (OS) with interferon (IFN) a2a with or without dacarbazine (DTIC) compared with observation alone.
Patients and methods: A total of 444 patients from 42 centers of the German Dermatologic Cooperative Oncology
Group who had received a complete lymph node dissection for pathologically proven regional node involvement were
randomized to receive either 3 MU s.c. of IFNa2a three times a week for 2 years (Arm A) or combined treatment with
same doses of IFNa2a plus DTIC 850 mg/m2 every 4–8 weeks for 2 years (Arm B) or to observation alone (Arm C).
Treatment was discontinued at first sign of relapse.
Results: A total of 441 patients were eligible for intention-to-treat analysis. Kaplan–Meier 4-year OS rate of those who
had received IFNa2a was 59%. For those with surgery alone, survival was 42% (A versus C, P = 0.0045). No
improvement of survival was found for the combined treatment Arm B with 45% survival rate (B versus C, P = 0.76).
Similarly, DFS rates showed significant benefit for Arm A, and not for Arm B. Multivariate Cox model confirmed that
Arm A has an impact on OS (P = 0.005) but not Arm B (P = 0.34).
Conclusions: 3 MU interferon a2a given s.c. three times a week for 2 years significantly improved OS and DFS in
patients with melanoma that had spread to the regional lymph nodes. Interestingly, the addition of DTIC reversed the
beneficial effect of adjuvant interferon a2a therapy.
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introduction
Cutaneous melanoma continues to be a major health problem
in Caucasian populations. Its incidence is increasing faster than
that of any other malignancy and it often affects younger
patients [1, 2]. Once distant metastasis develops, melanoma
is almost always fatal, with an estimated median survival range
of 6–12 months and a 5-year survival rate of 5% [3, 4].
However, in patients with melanoma that has spread to
the regional lymph nodes without recognizable further
metastasis, cure rates of up to 50% have been reported [4].
Considerable effort has been expended in attempts to identify
new active adjuvant treatment strategies for such patients
with high-risk melanoma before they develop visceral
metastases [5, 6].
A number of randomized trials have investigated the role of
interferon alpha (IFNa) as adjuvant therapy for high-risk
melanoma in stage II (primary melanoma with a tumor
thickness with >1.5 mm) [7, 8] and in stage III disease
(melanoma with spread to the regional lymph nodes with or
without skin metastases) [9–14]. Some of the adjuvant
interferon trials suggest a benefit at least for a prolongation of
disease-free survival (DFS) for IFNa, others showing no
statistically significant differences. Thus, there is a need for
more data to be accrued before definitive conclusions on the
role of adjuvant IFNa treatment in high-risk melanoma can be
reached [15].
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In spite of many other attempts to develop effective adjuvant
therapy for patients with high-risk melanoma, IFNa remains
the only agent which has demonstrated some therapeutic
activity. Dacarbazine (DTIC) chemotherapy has been examined
in the adjuvant setting in several trials and provided no survival
benefit, neither as a single agent nor in combination with
Bacille Calmette–Guerin or other nonspecific immunotherapy
[16–18]. In contrast, in melanoma patients with distant
metastasis, a meta-analysis on the combination of DTIC and
IFNa seemed to reveal higher response rates than single-agent
DTIC, but without a clear impact on a prolonged survival [19–
21]. Therefore, we examined the combination of IFNa plus
DTIC as an option to improve adjuvant treatment results.
The primary goal of the present trial was the improvement of
overall survival (OS), and secondary end points were
prolongation of recurrence-free survival and occurrence of
adverse events. In addition, health-related quality of life (QoL)
was measured by a questionnaire.
methods
patients
From February 1997 to September 2001, 444 patients with primary
melanoma that had spread to the draining lymph nodes were recruited into
a randomized clinical trial. The patients were treated at 42 centers
belonging to the Dermatologic Cooperative Oncology Group (DeCOG)
network in Germany and Switzerland (see appendix). The trial protocol was
approved by the central ethics committee of the University Medical Center
Tuebingen, Germany, and by ethics committees at all other participating
centers.
Patients with primary cutaneous malignant melanoma and pathologically
proven regional node metastases (either microscopic or macroscopic
metastasis) were eligible to enter the study. Only patients with a complete
lymphadenectomy and absence of satellite-, in-transit, or distant metastases
were eligible. Other inclusion criteria were age between 18 and 75 years’
absence of any other malignant disease apart from basal cell carcinoma; and
absence of cardiac, liver, renal, neurological, or autoimmune diseases.
Neither previous exposure to IFNa, concomitant use of corticosteroids, nor
other investigational drugs were allowed. Written informed consent was
obtained from each patient before entry into the study. A complete medical
history, physical examination, and laboratory tests (including blood count,
chemistry profile, and urine analysis) were obtained. All patients had at
least a chest radiograph and abdominal ultrasound or computed
tomography (CT) scans to exclude metastatic spread beyond the draining
lymph nodes.
study design
Metastatic spread to the regional lymph nodes was detected either clinically
at primary melanoma diagnosis or during follow-up examinations or by
means of sentinel lymph node biopsy. Radical dissection of the involved
regional lymph node basin was carried out before randomization, according
to the German guidelines on the treatment of melanoma. Patients were
randomly assigned to receive adjuvant INFa2a alone (Arm A), adjuvant
INFa2a plus DTIC (Arm B), or observation alone (Arm C). The aim of the
trial was to assess the efficacy and toxicity of Arm A and Arm B versus Arm
C. The main end point for efficacy was melanoma-specific survival. A fax
randomization was carried out at the University Medical Center Tuebingen
according to a permuted block randomization list, and no stratification was
employed. Figure 1 shows the trial profile.
Patients randomly assigned to receive INFa2a were given 3 MU s.c., three
times a week, and patients in the combined Arm B additionally received
DTIC 850 mg/m2 via i.v. infusion (20 min) on day 1 every 28 days during
the first 6 months, every 42 days during months 7–12, and every 56 days
during months 13–24. DTIC was administered in a light-protected infusion
system. All patients treated with INFa2a routinely received paracetamol
(2 · 500 mg) after the injection. Patients treated with DTIC received an
antiemetic treatment with setrones (tropisetron or ondansetron).
Treatment started within 6 weeks after removal of the lymph node
metastases and continued for 2 years. We discontinued treatment if
a patient developed severe or life-threatening adverse events thought to be
caused by INFa2a or by DTIC, or if local or distant metastases were
detected. Grade 4 toxic effects required permanent withdrawal of treatment.
Grade 3 toxic effects allowed subsequent treatment to be reintroduced at
reduced dosage levels (half dosage for interferon and DTIC was
recommended). Follow-up examinations took place every 3 months during
the entire study period or at any time when symptoms developed. At a 3
years follow-up after the end of therapy, patients had complete clinical
examination, blood tests, and lymph node ultrasound and every 6 months
chest radiograph and abdominal ultrasound or CT scans. The study was
monitored using on-site visits carried out by the DeCOG study center in
Tuebingen and independently audited by three academic clinical study
centers.
Health-related QoL was measured using a standardized questionnaire
developed by the European Organisation for Research and Treatment of
Cancer (EORTC) (QLQ-C30, Version 2.0) which is specifically tailored for
cancer patients [22]. The questionnaire was filled in every 3 months at the
follow-up examinations during the treatment period.
statistical methods
The study was designed to detect a treatment effect difference of 15% in the
4-year survival rate at a = 0.05 (estimates: observation group 25% versus
treatment groups 40%), with a power (1 2 b) of 0.80 on the basis of one-
sided testing. The sample size calculation required 134 assessable patients
per study arm, and assuming 10% dropouts for each arm, 148 patients had
to be included (total: 444 patients). Evaluation of the QLQ-C30
questionnaire has been carried out according to the recommendations of
the EORTC [22]. Patients’ characteristics in the different study arms and
the QoL scores were tested for differences by the chi-square test and the
Kruskal–Wallis test. Intention-to-treat population comprised all randomly
assigned patients who were eligible for this study. Per-protocol population
comprised eligible patients treated according to protocol; follow-up of
Figure 1. Trial profile. In each study arm there have been recorded three
nonmelanoma-related cases of death and these are included in the number
of deaths given here.
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patients with protocol violations was censored at the time of withdrawal
from the study. Follow-up of patients who died without relapse was
censored at the date of death. To calculate OS in the study arms, Kaplan–
Meier estimates were generated. Only deaths from melanoma were included
into the survival analysis. Survival times were calculated from the date of
randomization. Comparison of survival curves were drawn by log-rank test.
Additionally, Cox proportional hazards model was used to identify
important prognostic factors. Proportional hazards assumption was
assessed by the plot of the Schoenfeld residuals against time. Significance of
covariates was measured with the likelihood ratio test, and the role of each
covariate entering the model was assessed by the Wald statistic. Survival
plots were carried out according to the recommendations of Pocock and
colleagues [23] and the study report has been elaborated according to the
CONSORT statement [24]. Statistical analyses were carried out with the
statistical software SPSS 11.5 (SPSS Inc., Chicago, IL) and ‘‘The R Project
for Statistical Computing’’ version 1.8.0.
results
A total of 148 patients were randomly assigned to each of the
study arms (total 444) and 441 patients were eligible for the
intention-to-treat analysis (Figure 1). Table 1 shows the
characteristics of these patients. The study arms were well
balanced for all relevant prognostic factors for stage III
melanoma patients. Median follow-up time was 47 months.
The 4-year OS rate in patients who received single-agent
INFa2a was 59% compared with 42% for those who had
a lymph node dissection only (Table 2 and Figure 2). The
differences between the Kaplan–Meier melanoma-specific
survival curves were significant (P = 0.0045). There was no
significant difference between patients who received combined
treatment with INFa2a and DTIC with a 4-year OS rate of 45%
compared with untreated controls (P = 0.75). In each study
arm, there were only three patients with nonmelanoma-related
deaths, and if they are considered as events as well, the
treatment comparisons remained practically identical. Similar
results were found for 4-year recurrence-free survival rates
(RFS) with 39% for patients with single-agent INFa2a versus
27% RFS for patients with surgery alone (P = 0.018) and 29%
for patients with combined treatment (P = 0.97) (Table 2 and
Figure 3). The survival curve of patients treated with the
combination of INFa2a and DTIC virtually overlaps with the
survival curve of patients treated with surgery alone, indicating
that DTIC reverses beneficial effects of adjuvant INFa
treatment. In all, 420 of 441 patients (95%) received treatment
per protocol, and only 21 patients (Arm A 14; Arm B 4, and
Arm C 3 patients), who withdraw their informed consent and
received different treatments as planned, were classified as
protocol violators. The significant differences of the intention-
to-treat analysis were confirmed by the per-protocol analysis
(data not shown). Protocol violators and patients with
nonmelanoma-related deaths were both included into the
intention-to-treat analysis.
Table 3 shows a multivariate analysis of prognostic factors.
Patients with macroscopic involvement had a worse prognosis
(hazard ratio = 2.4, P < 0.0001) than those with microscopic
node involvement (sentinel node positivity). Furthermore,
patients with two to four and more than four positive nodes
had a worse outcome than those with one node only.
Treatment comparison (single-agent INFa2a versus
observation) adjusted for these two variables remained
significant (P = 0.005).
Toxicity was mild for INFa2a (Arm A) and for combined
treatment with INFa2a and DTIC (Arm B). Grade 3 and grade
4 adverse events were recorded in 13 patients of the treatment
Table 1. Patients’ characteristics
Characteristics Interferon
(n = 146)
Interferon plus
dacarbazine (148)
Surgery only
(n = 147)
Sex
Male 92 (63%) 93 (63%) 85 (58%)
Female 54 (37%) 55 (37%) 62 (42%)
Age (years)
0–40 29 (20%) 28 (19%) 27 (19%)
41–50 20 (14%) 30 (20%) 33 (23%)
51–60 48 (33%) 40 (27%) 33 (23%)
>60 49 (33%) 50 (34%) 52 (38%)
Two missing
Breslow depth of
primary melanoma (mm)
<1.5 45 (31%) 35 (24%) 36 (25%)
1.51–3 40 (27%) 49 (33%) 53 (36%)
3.01–4 13 (9%) 19 (13%) 16 (11%)
>4 30 (21%) 30 (20%) 28 (19%)
Not assessed 18 (12%) 15 (10%) 14 (9%)
Clark level
II 4 (3%) 4 (3%) 5 (3%)
III 33 (23%) 34 (23%) 31 (21%)
IV 72 (49%) 80 (54%) 78 (53%)
V 18 (12%) 12 (8%) 12 (8%)
Not assessed 19 (13%) 18 (12%) 21 (14%)
Site of primary
Head and neck 12 (8%) 8 (5%) 9 (6%)
Upper limbs 13 (9%) 16 (11%) 21 (14%)
Lower limbs 49 (34%) 48 (33%) 42 (29%)
Trunk 60 (41%) 64 (43%) 63 (43%)
Not otherwise specified 12 (8%) 12 (8%) 12 (8%)
Type of dissection
Axillary 61 (42%) 71 (48%) 79 (54%)
Groin (inguino-iliac) 63 (43%) 59 (40%) 55 (37%)
Laterocervical 18 (12%) 13 (9%) 10 (7%)
Other sites 4 (3%) 5 (3%) 3 (2%)
Clinical nodal status
N1a (microscopic
involvement)
32 (22%) 32 (22%) 40 (27%)
N1b (macroscopic
involvement)
110 (75%) 113 (76%) 103 (70%)
Not otherwise specified 4 (3%) 3 (2%) 4 (3%)
Disease status at entry
Primary 61 (42%) 66 (45%) 53 (36%)
Recurrent 76 (52%) 74 (50%) 86 (59%)
Not otherwise specified 9 (6%) 8 (5%) 8 (5%)
Number of positive nodes
1 69 (47%) 76 (51%) 61 (42%)
2–4 50 (34%) 41 (28%) 54 (37%)
>4 12 (8%) 14 (10%) 17 (11%)
Not assessed 15 (10%) 17 (11%) 15 (10%)
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arm with INFa2a and in 25 patients of the combined arm.
Premature termination of treatment due to toxicity or lack of
tolerability by the patient occurred in 38 patients, of these 20
patients in Arm A and in 16 patients in Arm B. No significant
differences were observed between both treatment arms. The
most common side-effects (grades 1–4) were leucocytopenia
(Arm A: 25%; B: 43%), nausea and vomiting (A: 15%; B: 40%),
elevation of liver enzymes (A: 22%; B: 24%), pain (A: 23%;
B: 18%), diarrhea (A: 11%; B: 17%), and fever (A: 11%; B:
15%), and grades 3 and 4 toxicity occurred in <2.5% of
patients; Table 4.
The QoL analysis compared the different scores of the
EORTC QLQ-C30 questionnaire at baseline and 6 months after
randomization in a total of 238 patients. Six-month values were
Table 2. Univariate analysis on overall and disease-free survival
Treatment arm Hazard
ratio
97.5% CI 4-year
rate %
97.5% CI
Overall survival
Surgery only 1.0 42.4 32.9; 52.1
Interferon 0.62 0.42; 0.89 59.0 49.4; 68.6
Interferon plus
dacarbazine
0.96 0.67; 1.33 45.2 35.6; 54.8
Disease-free survival
Surgery only 1.0 27.3 18.8; 35.8
Interferon 0.69 0.49; 0.96 39.0 29.4; 48.6
Interferon plus
dacarbazine
1.01 0.72; 1.36 29.4 20.7; 38.1
Figure 2. Kaplan–Meier overall survival.
Figure 3. Kaplan–Meier disease-free survival.
Table 3. Multivariate analysis on survival (Cox hazard regression
model)
Variable Hazard
ratio
Standard
error
97.5% CI P value
Clinical nodal status
N0 (microscopic
involvement)
1.000
N1b (macroscopic
involvement)
2.427 0.197 1.986; 2.868 <0.0001
Nodes
1 positive 1.000
2–4 positive 1.490 0.220 0.997; 1.983 0.070
>4 positive 1.335 0.152 0.995; 1.675 0.057
Treatment arm
Surgery only 1.000
Interferon 0.609 0.178 0.210; 1.008 0.005
Interferon plus
dacarbazine
0.854 0.166 0.482; 1.226 0.343
Table 4. Grade 3 + 4 toxicity
IFNa IFNa plus DTIC
Grade 3 Grade 4 Grade 3 Grade 4
Anemia 0.8% – 2.5% –
Leukopenia – – 2.5% –
Granulopenia – – 0.8% –
Thrombozytopenia 0.8% – 0.8% –
Liver enzyme elevation
(AP/SGOT)
– – 0.8% –
Nausea/emesis 0.8% – 1.6% –
Diarrhea 1.6% – – –
Constitutional/fever – – – –
Allergy – 0.8%
Skin 0.8% – 0.8% –
Pulmonary – – 0.8% –
Infection 0.8% – 0.8% –
Consciousness 1.6% 0.8% 1.6% –
Peripheral nerves – – 0.8% –
Pain 1.6% – 1.6% –
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calculated as percent of baseline values (Figure 4). Interestingly,
patients under adjuvant treatment had a better outcome for the
general dimensions of QoL as ‘physical functioning’ (Arm A
versus Arm C: P = 0.007), ‘role functioning’ (Arm A versus
Arm C: P = 0.008), and ‘emotional functioning’ (Arm A versus
Arm C: P = 0.048) in comparison to the patients treated with
surgery only. However, patients in the adjuvant treatment arms
displayed more drug-related symptoms such as the ‘fatigue
symptom scale’ (Arm A versus Arm C: P = 0.036) and those
treated with DTIC also for the ‘nausea and vomiting scale’
(Arm B versus Arm C: P = 0.037).
discussion
This clinical trial demonstrated two major findings: (i)
melanoma patients with metastatic spread to regional lymph
nodes had a significantly improved DFS and OS when they
received low-dose single-agent INFa2a for 2 years and (ii)
patients who were treated with the combination of INFa2a and
DTIC did not show an improved DFS or OS compared with
those with observation alone.
It is an unusual finding in this study that the OS benefit is
larger than the DFS benefit. In most other studies the reverse
has been observed. The present study is part of a series of
smaller studies that have addressed the role of low-dose IFNa
and it should be mentioned the possibility that the play of
chance may have been a factor in that way, that some trials will
underestimate the treatment effect and some will overestimate
it. The latter may be true in the present trial.
DTIC was added to INFa2a because a meta-analysis in stage
IV melanoma patients showed an improvement of the response
rates. However, no effect on the OS time was observed [25].
This phase III trial wanted to evaluate the OS time in patients
who were treated in the adjuvant setting with IFNa with or
without DTIC compared with observation alone. DTIC
reversed the improvement of OS that was achieved in the study
arm treated with INFa2a alone. Possible explanations are the
immunosuppressive effects of DTIC [26, 27] which might
counteract the immunostimulatory effects of INFa2a. In
addition, exposure of melanoma cells to DTIC might lead to
enhanced tumor growth and metastasis, as evidenced by
a recent mouse model [28, 29].
An imbalance of prognostic factors between the treatment
groups can be widely excluded as a reason for the survival
differences. Particularly, the number of positive lymph nodes,
the disease status at study entry, and the nodal status in
accordance to the tumor–node–metastasis (TNM) classification
[30–32] did not differ significantly between the arms. However,
we did not document a possible ulceration of the primary
tumor because this was not part of the TNM/American Joint
Committee on Cancer classification system at the initiation of
this clinical trial. To our best knowledge, there are no patient
characteristics which could explain the significant OS and
relapse rate differences between single-agent INFa2a and the
comparator arms. Whereas 60.1% of patients treated with IFNa
and DTIC died during the observation period, in the untreated
control arm a comparable number (59.9%) deceased. In
contrast, only 44.5% of patients treated with single-agent
INFa2a died due to metastatic melanoma.
The finding of a significant survival improvement for single-
agent INFa2a compared with surgery alone is difficult to
interpret. There are at least four clinical trials, in which patients
have been treated with low-dose IFNa for stage III disease [9–
12]. These trials were neither able to demonstrate a significant
improvement for relapse-free survival nor for OS. Therefore,
this clinical trial is in clear contrast to the previously published
multicenter trials in the same setting. The reasons are not
obvious for us since the selection of patients did not differ
Figure 4. Quality of life (QoL) dimensions at 6 months after randomization. Six-month values were calculated as percent of baseline values and higher
values indicate deterioration of QoL.
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significantly from the other trials. Dosage does not play
a significant role as all these clinical trials used low-dose IFNa
thrice a week. In a recent publication, Stadler et al. showed that
a combined treatment with DTIC and IFNa was associated with
improvement of prognosis compared with surgery alone. The
schedule utilized in this study was quite different from ours:
DTIC and IFNa were not given simultaneously, but DTIC was
given for only two cycles and then the IFNa treatment was
subsequently added. In this case, the DTIC may not negatively
affect the immunological treatment. The study does not test the
question whether the application of DTIC adds anything to the
effect of IFNa [33].
Recent meta-analyses of 12 adjuvant IFNa trials in high-risk
melanoma patients demonstrated that IFNa prolongs
recurrence-free survival in a subgroup of melanoma patients. A
17% reduction in the risk of recurrence has been calculated.
However, the effect on a prolongation of OS is less convincing
with a 7% reduction in the risk of death [15, 34].
It is obvious that most of the clinical trials which have been
carried out in the adjuvant treatment of malignant
melanoma—including the present study—were underpowered.
Therefore, the chance to detect statistical significant differences
in DFS or OS is relatively low. A more careful selection of
patients who are likely to benefit from adjuvant IFNa is
mandatory. Unfortunately, predictive factors for melanoma
patients treated with IFNa have not been established yet. Even
in a large-sized EORTC trial on 1388 patients with thick
primary tumors or regional lymph node metastases only,
a small increase (7.2%) in the distant metastases-free interval
and a 5.4% improvement in OS have been detected after
a median follow-up of 4.65 years. The differences were not
statistically significant [35].
In conclusion, adjuvant INFa2a treatment with low dosages
in a homogenous group of patients with first manifestation of
metastasis in regional lymph nodes improved DFS and OS.
However, the combination of INFa2a with the cytotoxic agent
DTIC reversed this beneficial effect in this randomized trial.
Although only 444 patients have been randomized, the results
are remarkable since they reached statistical significance due to
the impressive different numbers in the death and relapse rates.
There are no obvious reasons to believe a bias between the
groups, but the impact of INFa in the adjuvant treatment of
melanoma remains controversial due to heterogeneous results
in the literature. Most likely, no further large-sized clinical trials
on conventional IFNa will be initiated since multinational trials
on pegylated INFa2a and pegylated INFa2b are already
underway in the adjuvant treatment of high-risk melanoma
patients.
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